The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical ... cancer, with additional studies to be conducted in other ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

In fact, 25 percent of cervical cancer diagnoses occur in women over the age of 65, and cervical cancers diagnosed in this ...

Denmark is working towards eliminating cervical cancer by 2040. The Danish Cancer Society announced this initiative. A national HPV vaccination campaign and screening program are underway.

New research suggests that an “often-overlooked” parasitic infection, already linked to bladder cancer, may also raise the risk of cervical cancer.

Researchers at AIIMS, Delhi have developed a simple blood test using droplet digital PCR (ddPCR) to track the effectiveness of cervical cancer treatment. Published in Scientific Reports ...

Researchers discovered that S. haematobium infection can trigger changes in gene activity associated with cancer development in the cervical lining, and alarmingly, these changes intensify ...

Denmark aims to eradicate cervical cancer by 2040 thanks to a national HPV vaccination campaign and screening program, the Danish Cancer Society said on Monday. "Even before 2040, so few women may ...

A new study finds that Schistosoma haematobium infection, and its treatment, can activate cancer-related genes in the cervix, ...